Denali Advisors’s ALX Oncology ALXO Stock Holding History

Denali Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,500	Closed	-$72K	–	420
2022 Q3	$72K	Buy	+7,500	New	+$87.4K	0.03%	186

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Denali Advisors's ALXO Position: Q4 2022 in Review

Denali Advisors sold out of ALX Oncology (ALXO) in Q4 2022, closing a stake of 7,500 shares — an estimated $72K sold.

Denali Advisors first reported a position in ALXO in Q3 2022 and held it in 1 quarter. The position peaked at $72K in Q3 2022. 87 funds tracked by Wall St. Rank hold ALXO as of Q4 2022.

Denali Advisors reported no remaining ALX Oncology position as of Q4 2022 after selling out during the quarter.
Denali Advisors sold 7,500 ALX Oncology shares in Q4 2022, an estimated $72K.
Denali Advisors first reported a position in ALX Oncology in Q3 2022 and held it in 1 quarter.
Denali Advisors's ALX Oncology position peaked at $72K in Q3 2022.
87 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2022.

Based on Denali Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.